CDX-2 expression in colorectal cancer: A single centre study from Pakistan
Introduction: Tumors of the gastrointestinal (GI) tract, share a major burden for mortality and morbidity all over the world. The most common site of carcinoma of GIT is colon and rectum (70%). The etiological factors may be environmental (diet) and genetic. CDX-2 has been proposed as being present in most of the cases with colorectal carcinoma.
Objective: To determine the frequency of positive expression of CDX2 in diagnosed cases of colorectal adenocarcinoma diagnosed on haematoxylin and eosin stain.
Material and Methods:
This was a cross-sectional study and was conducted at ---(deleted for blind review)--- over period of 2 years We included all paraffin embedded tissue sections of colorectal carcinoma of both genders with an age range of 25-75 years. Specimens were stained with Heamatoxylin and Eosin (H & E) and examined microscopically for presence or absence of invasive cancer. Another specimen was taken and stained with CDX2. The data were analyzed using SPSS version 24.
Results: A total of 125 cases with colorectal carcinoma diagnosed on H & E stain were included in the study. The mean age of the patients was found to be 52.66 ± 14.62 years. In this study, 67 patients (53.6%) were male and 58 patients (46.4%) were having final diagnosis of Adenocarcinoma. Regarding the site, most common lesion involved rectum, followed by sigmoid colon and ascending colon. Among 125 specimens reviewed, 112 patients (89.6%) were CDX-2 positive while 13 patients (10.4%) were CDX-2 negative. Also we stratified the CDX-2 expression according to site and type of colorectal carcinoma and was found significant for both of these (P<0.05).
Conclusion: We concluded that CDX-2 was present in almost 90% of colorectal carcinoma specimens so it can be used as an important diagnostic tool for colorectal carcinoma during histopathological diagnosis.
Keywords: Colorectal carcinoma; CDX-2; Hematoxylin; Eosin
2. Lang JJ, Alam S, Cahill LE, Drucker AM, Gotay C, Kayibanda JF, et al. Global burden of disease study trends for canada from 1990 to 2016. Can Med Assoc J. 2018;190(44):E1296-e304.
3. Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody. Diagn Pathol. 2012;7:9.
4. Bayrak R, Yenidunya S, Haltas H. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol Res Pract. 2011;207(3):156-60.
5. Saad RS, Ghorab Z, Khalifa MA, Xu M. CDX2 as a marker for intestinal differentiation: Its utility and limitations. World J Gastrointest Surg. 2011;3(11):159-66.
6. Dawson H, Galvan JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, et al. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer. 2014;134(10):2342-51.
7. Dai ZM, Fei YL, Zhang WG, Liu J, Cao XM, Qu QM, et al. Association of Vitamin D Receptor Cdx-2 Polymorphism With Cancer Risk: A Meta-Analysis. Medicine. 2015;94(33):e1370.
8. Sen A, Mitra S, Das RN, Dasgupta S, Saha K, Chatterjee U, et al. Expression of CDX-2 and Ki-67 in different grades of colorectal adenocarcinomas. Indian J Pathol Microbiol. 2015;58(2):158-62.
9. Elzouki AN, Habel S, Alsoaeiti S, Abosedra A, Khan F. Epidemiology and clinical findings of colorectal carcinoma in two tertiary care hospitals in Benghazi, Libya. Avicenna J Med. 2014;4(4):94-8.
10. Hassan C, Senore C, Radaelli F, De Pretis G, Sassatelli R, Arrigoni A, et al. Full-spectrum (FUSE) versus standard forward-viewing colonoscopy in an organised colorectal cancer screening programme. Gut. 2017;66(11):1949-55.
11. Young JP, Win AK, Rosty C, Flight I, Roder D, Young GP, et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J Gastroenterol Hepatol. 2015;30(1):6-13.
12. Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol. 2013;24(10):2657-71.
13. Bhurgri Y, Khan T, Kayani N, Ahmad R, Usman A, Bhurgri A, et al. Incidence and current trends of colorectal malignancies in an unscreened, low risk Pakistan population. Asian Pac J Cancer Prev. 2011;12(3):703-8.
14. Sung JJ, Lau JY, Goh KL, Leung WK, Asia Pacific Working Group on Colorectal C. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6(11):871-6.
15. Phipps AI, Chan AT, Ogino S. Anatomic subsite of primary colorectal cancer and subsequent risk and distribution of second cancers. Cancer. 2013;119(17):3140-7.
16. Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27(3):303-10.
17. Kaimaktchiev V, Terracciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol. 2004;17(11):1392-9.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.